Graduated systemic treatment of AIDS-associated Kaposi sarcoma: In the era of highly active antiretroviral therapy

American Journal of Cancer

Volumn 3, Issue 3, 2004, Pages 133-149

  Hengge, Ulrich R ^a   Tossing, Gudrun ^b   Kouri, Vivian ^c   Fruehauf, Stefan ^d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Essex Pharma GmbH   (Germany)

^c INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; BLEOMYCIN; CYTOKINE; DAUNORUBICIN; DOXORUBICIN; EMD 121976; FUMAGILLIN; IM 862; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEMAXANIB; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ZIDOVUDINE;

ADVANCED CANCER; AIDS ASSOCIATED KAPOSI SARCOMA; ALOPECIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER INCIDENCE; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; DISEASE SEVERITY; DRUG SELECTIVITY; DRUG TARGETING; FATALITY; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNOSTIMULATION; KAPOSI SARCOMA; LEUKOPENIA; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PREVALENCE; PRIORITY JOURNAL; RASH; REMISSION; REVIEW; SIDE EFFECT; SKIN TINGLING; STOMATITIS; TREATMENT OUTCOME; VIRULENCE; VIRUS CARCINOGENESIS; XEROSIS;

EID: 4544299701     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200403030-00001     Document Type: Review

References (166)

1. Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. Arch Derm Syph 1872; 4: 742-9
2. Snover DC, Rosai J. Vascular sarcomas of the skin. In: Wick MR, editor. Clinical and biochemical analysis. Vol. 20. New York: Marcel Dekker, 1985: 181-209
3. Taylor JF, Templeton AC, Vogel CL, et al. Kaposi's sarcoma in Uganda: a clinicopathologic study. Int J Cancer 1971; 8: 122-35
4. Hiesse C, Kriaa F, Rieu P, et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and cyclosporine-treated recipients: analysis of a 20-year period in 1600 patients. Transplant Proc 1995; 27: 972-4
5. Friedman-Kien AE. Disseminated Kaposi's sarcoma syndrome in young homosexual men. J Am Acad Dermatol 1981; 5: 468-71
6. Beral V, Peterman TA, Berkelman RL, et al. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990; 335: 123-8
7. Miles SA. Pathogenesis of HIV-related Kaposi's sarcoma. Curr Opin Oncol 1994; 6: 497-502
8. Armes JC. A review of Kaposi's sarcoma. Adv Cancer 1989; 53: 73-87
9. Ensoli B, Barillari G, Gallo RC. Pathogenesis of AIDS-associated KS. Hematol Oncol Clin North Am 1991; 5: 281-95
10. Stürzl M, Brandstetter H, Roth WK. Kaposi's sarcoma: a review of gene expression and ultrastructure of KS spindle cells in vivo. AIDS Res Hum Retroviruses 1992; 8: 1753-62
11. Jablonowski H. Interferons in Kaposi's sarcoma. In: Aul C, editor. Interferons: biolog activities, clinical efficacy. Berlin Heidelberg: Springer-Verlag, 1997: 196-216
12. Gill PS. Pathogenesis of HIV-related malignancies. Curr Opin Oncol 1991; 3: 867-71
13. Ensoli B, Barillari G, Gallo RC. Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma. Immunol Rev 1992; 127: 147-55
14. Williams AO, Ward JM, Li JF, et al. Immunohistochemical localization of transforming growth factor -β1 in Kaposi's sarcoma. Hum Pathol 1995; 26: 469-73
15. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2002; 2: 344-52
16. Albini A, Barillari G, Benelli R, et al. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci U S A 1995; 2392: 4838-42
17. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371: 674-80
18. Maitra RK, McMillan NA, Desai S, et al. HIV-1 Tat RNA has an intrinsic ability to activate interferon-inducible enzymes. Virology 1994; 204: 823-7
19. Miles SA. Pathogenesis of human immunodeficiency virus-related Kaposi's sarcoma. Curr Opin Oncol 1992; 4: 875-82
20. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 267: 1078-80
21. Goebel F-D, Jablonowski H. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma. Eur J Med Res 1999; 4: 507-13
22. Zong J, Ciufo DM, Viscidi R, et al. Genotypic analysis at multiple loci across Kaposi's sarcoma herpesvirus (KSHV) DNA molecules: clustering patterns, novel variants and chimerism. J Clin Virol 2002; 23: 119-48
23. Moore PS, Gao SJ, Dominguez G, et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. J Virol 1996; 70: 549-58
24. Sarid R, Sato T, Bohensky RA, et al. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med 1997; 3: 293-8
25. Bais C, Santomasso B, Coso O, et al. Kaposi's sarcoma-associated human herpesvirus-8 is a viral oncogene and angiogenesis activator. Nature 1998; 391: 86-9
26. Wu H, Mitra D, Mesri E, et al. Human herpes viruses-8 (HHV-8)-mediated CD4(+) T-cell lymphopenia [abstract no. 437]. 5th Conf Retrovir Opport Infect 1998, 161
27. Kedes DH, Operskalski E, Busch M, et al. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission, Nat Med 1996; 2: 918-24
28. Simpson GR, Schulz TF, Whitby D, et al. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 1996; 346: 1133-8
29. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995; 346: 799-802
30. Gao SJ, Kingsley L, Hoover DR, et al, Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma, N Engl J Med 1996; 335: 233-41
31. Martin JN, Ganem DE, Osmond DH, et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338: 948-54
32. Oksenhendler E, Cazals-Hatem D, Schulz TF, et al. Transient angiolymphoid hyperplasia and Kaposi's sarcoma after primary infection with human herpesvirus 8 in a patient with human immunodeficiency virus infection. N Engl J Med 1998; 338: 1585-90
33. Ziegler JL, Katongole-Mbidde E. Kaposi's sarcoma in childhood: an analysis of 100 cases from Uganda and relationship to HIV infection. Int J Cancer 1996; 65: 200-3
34. Wabinga HR, Parkin DM, Wabwire-Mangen F, et al. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int J Cancer 1993; 54: 26-36
35. Jones JL, Hanson DL, Dworkin MS, et al. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group. J Acquir Immune Defic Syndr 1999; 21: S11-7
36. Sitas F, Newton R. Kaposi's sarcoma in South Africa. J Natl Cancer Inst 2001; 28: 1-4
37. Purvis SF, Katongole-Mbidde E, Johnson JL, et al. High incidence of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in tumor lesions and peripheral blood mononuclear cells from patients with Kaposi's sarcoma in Uganda. J Infect Dis 1997; 175: 947-50
38. Hermans P. Epidemiology, etiology and pathogenesis, clinical presentations and therapeutic approaches in Kaposi's sarcoma: 15-year lessons from AIDS. Biomed Pharmacother 1998; 52: 440-6
39. Ensoli B, Gallo RC. Pathogenesis of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin North Am 1991; 5: 281-95
40. Hermans P, Franchioly PPP, Thioux C. et al. Possible role of granulocytemacrophage colony stimulating factor (GM-CSF) on the rapid progression of AIDS related Kaposi's sarcoma lesions in vivo. Br J Haematol 1994; 345: 84-6
41. Wang CY, Schroeter AL, Su WP. Acquired immunodeficiency syndrome-related Kaposi's sarcoma. Mayo Clin Proc 1995; 70: 869-79
42. Samaniego F, Markham PD, Gallo RC, et al. Inflammatory cytokines induce AIDS-Kaposi's sarcoma-derived spindle cells to produce and release basic fibroblast growth factor and enhance Kaposi's sarcoma-like lesion formation in nude mice. J Immunol 1995; 154: 3582-92
43. Neipel F, Albrecht JC, Fleckenstein B. Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? J Virol 1997; 71: 4187-92
44. Albrecht JC, Nicholas J, Biller D, et al. Primary structure of the herpesvirus saimiri genome. J Virol 1992; 66: 5047-58
45. Neipel F, Albrecht JC, Ensser A, et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol 1997; 71; 839-42
46. Sun R, Lin SF, Staskus K, et al. Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol 1999; 73: 2232-42
47. Moore PS, Boshoff C, Weiss RA, et al. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996; 274: 1739-44
48. Renne R, Barry C, Dittmer D, et al. Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol 2001; 75: 458-68
49. Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 1999; 96: 4546-51
50. Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000; 6: 1121-7
51. Monini P, Colombini S, Sturzl M, et al. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood 1999; 93: 4044-58
52. Jones KD, Aoki Y, Chang Y, et al. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 1999; 94: 2871-9
53. Chang J, Renne R, Dittmer D, et al. Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. Virology 2000; 266: 17-25
54. Russo JJ, Bohenzky RA, Chien MC, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A 1996; 93: 14862-7
55. Cesarman E, Nador RG, Bai F, et al. Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J Virol 1996; 70: 8218-23
56. Arvanitakis L, Geras-Raaka E, Varma A, et al. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 1997; 385: 347-50
57. Lee H, Veazey R, Williams K, et al. Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat Med 1998; 4: 435-40
58. Osborne J, Moore PS, Chang Y. KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum Immunol 1999; 60: 921-7
59. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998; 391: 86-9
60. Yang TY, Chen SC, Leach MW, et al. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 2000; 191: 445-54
61. Cheng EH, Nicholas J, Bellows DS, et al. A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci U S A 1997; 94: 690-4
62. Sarid R, Sato T, Bohenzky RA, et al. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med 1997; 3: 293-8
63. Cannon M, Cesarman E. Kaposi's sarcoma-associated herpes virus and acquired immunodeficiency syndrome-related malignancy. Semin Oncol 2000; 27: 409-19
64. Thome M, Schneider P, Hofmann K, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997; 386: 517-21
65. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis 2002; 2: 281-92
66. Krown SE, Real EX, Krim M, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 1983; 308: 1071-6
67. Baca-Regen L, Heinzinger N, Stevenson M, et al. Alpha interferon-induced antiretroviral activities: restriction of viral nucleic acid synthesis and progeny virion production in human immunodeficiency type 1-infected monocytes. J Virol 1994; 68: 7559-65
68. Ho DD, Hartshorn KL, Rota TR, et al. Recombinant human interferon-alpha-A suppresses HTLV-III replication in vitro. Lancet 1985; 1: 602-4
69. Evans LM, Itri LM, Campion M, et al. Interferon-alfa-2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Immunother 1991; 10: 39-50
70. Real FX, Oettgen HF, Krown SE. Kaposi's sarcoma and the acquired immune deficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 1986; 4: 544-51
71. Krown SE, Real EX, Krim M, et al. Recombinant leukocyte A interferon in Kaposi's sarcoma. Ann N Y Acad Sci 1984; 437: 431-7
72. Gelmann EP, Preble OT, Steis R, et al. Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome: clinical response and prognostic parameters. Am J Med 1985; 78: 737-41
73. Vadhan-Raj S, Wong G, Gnecco C, et al. Immunological variables in patients with Kaposi's sarcoma and the acquired immune deficiency syndrome. Cancer Res 1986; 46: 417-25
74. Mildvan D, Bassikios Y, Zucker ML, et al. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: ACTG 068. Antiviral Ther 1996; 1: 77-88
75. Krown SE, Niedzwiecki D, Bhalla RB, et al. Relationship and prognostic value of endogenous IFN-alpha, β2-microglobuline, and neopterin serum levels in patients with Kaposi's sarcoma and AIDS. J Acquir Immune Defic Syndr 1991; 4: 871-80
76. Mildvan D, Machado SG, Wilets I, et al. Endogenous IRM and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 1992; 339: 453-6
77. Shepherd FA, Beaulieu R, Gelmon K, et al. Prospective randomised trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network Study. J Clin Oncol 1998; 16: 1736-42
78. Krown SE, Gold JWM, Niedwiecki D, et al. Interferon and zidovudine: safety, tolerance, and clinical and virological effects in patients with Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 112: 812-21
79. Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur J Cancer 2001; 37: 1288-95
80. Mauss S, Jablonowski H. Efficacy, safety and tolerance of low-dose, long-term interferon-alfa2b and zidovudine in early-stage AIDS-associated Kaposi's sarcoma. J Acquir Immune Defic Syndr 1995; 2: 157-62
81. Tossing G. The role of endogenous interferon-alpha in HIV-infection and autoimmune diseases: an overview. In: Aul C, editor. Interferons: biolog activities, clinical efficacy. Berlin Heidelberg: Springer-Verlag, 1997: 14-25
82. Hess G, Rossol S, Rossol R, et al. TNF and IFN as prognostic markers in HIV-infection. Infection 1991; 19: 93-7
83. Torres G. Use of IFN-alpha in HIV-disease. In: Jäger H, editor. AIDS: Eine Krankheit wird behandelbar. Landsberg: Ecomed Verlagsgesellschaft, 1993: 189-93
84. Rossol S, Voth R, Laubenstein HP, et al. IFN-production in patients infected with HIV-1. J Infect Dis 1989; 159: 815-21
85. Lau AS, Livesey JF. Endotoxin induction of TNF is enhanced by acid-labile alpha-IFN in AIDS. J Clin Invest 1989; 84: 738-43
86. Poli G, Biswas P, Fauci AS. IFN's in the pathogenesis and treatment of HIV-infection. Antiviral Res 1994; 24: 221-33
87. Schröder HC, Müller WEG, Pfleiderer W. With oligoadenylates and intracellular immunity against retroviruses. Nachr Chem Tech Lab 1992; 40: 1352-60
88. Cohen B, Gothelf Y, Vaiman D, et al. IL-6 induces the 2-5 oligoadenylate synthetase gene in M1 cells through an effect on the IFN-responsive enhancer. Cytokine 1991; 3: 83-91
89. Von Wussow P, Jakschies D, Hochkeppel HK, et al. The human intracelllular Mx-homologous protein is specifically induced by type I IFN's. Eur J Immunol 1990; 20: 2015-9
90. Jakschies D, Zachaval R, Müller R, et al. Strong transient expression of the type I IFN-induced MxA protein in hepatitis A, but not in acute hepatitis B and C. Hepatology 1994; 19: 857-65
91. Antinori A, Izzi I, Ammassari A, et al. Evaluation of different staging systems for Kaposi's sarcoma in HIV-infected patients. J Cancer Res Clin Oncol 1992; 118: 635-6
92. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989; 7: 1201-7
93. Francis ND, Parkin JM, Weber J, et al. Kaposi's sarcoma in acquired immune deficiency syndrome (AIDS). J Clin Pathol 1986; 39: 469-74
94. Collaborative Group on AIDS incubation and HIV Survival including the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before wide-spread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000; 355: 1131-7
95. Hengge UR, Esser S, Rudel HP, et al. Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. Eur J Cancer 2001; 37: 878-83
96. Hortobagyi GN. Anthracyclines in the treatment of cancer: an overview. Drugs 1997; 54: 1-7
97. Hengge UR, Brockmeyer NH, Baumann M, et al. Liposomal doxorubicin treatment of AIDS-related Kaposi's sarcoma [letter]. Lancet 1993; 342: 497
98. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996; 380: 561-2
99. Martin FJ. STEALTH liposome technology: an overview. DOXIL Clinical Series 1996; 1: 1-8
100. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-92
101. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumour localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996; 36: 55-63
102. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998; 16: 683-91
103. Northfelt DW, Dezube BJ, Thommes JA. Pegylated liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine (ABV) in the treatment of AIDS-related Kaposi's sarcoma: results of a randomised phase III clinical trial. J Clin Oncol 1998; 16: 2445-51
104. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14: 2353-64
105. Rosenthal E, Poizot-Martin I, Saint-Marc T, et al. Phase IV study of lipsomal daunorubicin (DuanoXome) in AIDS-related Kaposi sarcoma. Am J Clin Oncol 2002; 25 (1): 2353-64
106. Tulpule A, Yung RC, Wernz J, et al. Phase II trial of lipsomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. J Clin Oncol 1998; 16 (10): 3369-74
107. Bennett CL, Golup RM, Stinson TJ, et al. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirus 1998; 18: 460-5
108. Osoba D, Northfelt DW, Budd DW, et al. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS): related Kaposi's sarcoma: a randomised trial of pegylated liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest 2001; 19: 573-80
109. Hengge UR, Brockmeyer NH, Rasshofer R, et al. Fatal hepatic failure with liposomal doxorubicin. Lancet 1993; 341: 383-4
110. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 1999; 17: 1876-83
111. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 1998; 16: 1112-21
112. Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 2002; 95: 147-54
113. Aboulafia DM, Norris D, Henry D, et al. 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial. Arch Dermatol 2003; 139: 178-86
114. Bernstein ZP, Chanan-Khan A, Miller KC, et al. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Cancer 2002; 95: 2555-61
115. Ledergerber B, Telenti A, Effer M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. BJM 1999; 319: 23-4
116. Murphy M, Armstrong D, Sepkowitz KA, et al. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 1997; 11: 261-2
117. Aboulafia DM. Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy. Mayo Clin Proc 1998; 73: 439-43
118. Levine AM, Tulpule A. Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur J Cancer 2001; 37: 1288-95
119. Cattelan A, Calabro M, Gasperini P, et al. Acquired immune deficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 2001; 28: 44-9
120. Boivin G, Gaudreau A, Routy JP. Evaluation of the human herpes virus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy. AIDS 2000; 14: 1907-10
121. Strickler HD, Goedert JJ, Bethke FR, et al. Human herpesvirus 8 cellular immune responses in homosexual men. J Infect Dis 1999; 180: 1682-5
122. Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma: associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31: 384-90
123. Esdaile B, Davis M, Portsmouth S, et al. The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma. AIDS 2002; 16: 2344-7
124. Toschi E, Sgadari C, Monini P, et al. Treatment of Kaposi's sarcoma-an update. Anticancer Drugs 2002; 13: 977-87
125. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs: implications for potential therapy. J Clin Invest 1997; 99: 2082-6
126. Robles R, Lugo D, Gee L, et al. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 34-8
127. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340: 1063-70
128. Cordero E, Lopez-Cortes LF, Viciana P, et al. Foscarnet and AIDS-associated Kaposi's sarcoma. AIDS 1997; 11: 1787-8
129. Hammoud Z, Parenti DM, Simon GL. Abatement of cutaneous Kaposi's sarcoma associated with cidofovir treatment. Clin Infect Dis 1998; 26: 1233
130. Little RF, Merced-Galindez F, Staskus K, et al. A pilot study of cidofovir in patients with Kaposi sarcoma. J Infect Dis 1998; 187: 149-53
131. Tappero JW, Berger TG, Kaplan LD, et al. Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial. J Acquir Immune Defic Syndr 1991; 4: 839-46
132. Brenner B, Rakowsky E, Katz A, et al. Tailoring treatment for classical Kaposi's sarcoma: comprehensive clinical guidelines. Int J Oncol 1999; 14: 1097-1102
133. Holecek MJ, Harwood AR. Radiotherapy of Kaposi's sarcoma. Cancer 1978; 41: 1733-8
134. el-Akkad S, Bull CA, el-Senoussi MA, et al. Kaposi's sarcoma and its management by radiotherapy. Arch Dermatol 1986; 122: 1396-9
135. Groopman JE, Gottlieb MS, Goodman J, et al. Kaposi's sarcoma in AIDS: the role of radiation therapy. Front Radiat Ther Oncol 1985; 19: 126-32
136. Nisce LZ, Safai B, Poussin-Rosillo H. Once weekly total and subtotal skin electron beam therapy for Kaposi's sarcoma. Cancer 1981; 47: 640-4
137. Berson AM, Quivey JM, Harris JW, et al. Radiation therapy for AIDS-related Kaposi's Sarcoma. Int J Radiat Oncol Biol Phys 1990; 19: 569-75
138. de Wit R, Smit WG, Veenhof KH, et al. Palliative radiation therapy for AIDS-associated Kaposi's sarcoma by using a single fraction of 800 cGy. Radiother Oncol 1990; 19: 131-6
139. Stelzer KJ, Griffin TW. A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1993; 27: 1057-61
140. Watkins EB, Findlay P, Gelmann E, et al. Enhanced mucosal reactions in AIDS patients receiving oropharyngeal irradiation. Int J Radiat Oncol Biol Phys 1987; 13: 1403-8
141. Schweitzer VG, Visscher D. Photodynamic therapy for treatment of AIDS-related oral Kaposi's sarcoma. Otolaryngol Head Neck Surg 1990; 102: 639-49
142. Marchell N, Alster TS. Successful treatment of cutaneous Kaposi's sarcoma by the 585-nm pulsed dye laser. Dermatol Surg 1997; 23: 973-5
143. Epstein JB, Lozada-Nur F, McLeod WA, et al. Oral Kaposi's sarcoma in acquired immunodeficiency syndrome: review of management and report of the efficacy of intralesional vinblastine. Cancer 1989; 64: 2424-30
144. Boudreaux AA, Smith LL, Cosby CD, et al. Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome: a clinical trial to evaluate efficacy and discomfort associated with infection. J Am Acad Dermatol 1993; 28: 61-5
145. Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 1999; 22: 235-46
146. Bodsworth NJ, Bloch M, Bower M, et al. International Panretin Gel KS Study Group. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol 2001; 2: 77-87
147. Tossing G. New developments in interferon therapy. Eur J Med Res 2001; 6: 47-65
148. Tossing G. New perspectives in anti-HIV treatment strategies: structured therapy interruptions and immunemodulatory cytokines. Current News No. 222, Supplement to Infection 2001; 29: 1-4
149. Nieto L, Angel J, Gazzard B, et al. Antiviral activity and tolerability of PegIntron in HIV patients failing HAART [abstract 115]. The 1st IAS Conference on HIV Pathogenesis and Treatment; 2001 Jul 8-11; Buenos Aires
150. Hatzakis A, Gargalianos P, Kiosses V, et al. Low dose interferon-alfa monotherapy in treatment-naïve individuals with HIV-1 infection: evidence of potent suppression of viral replication. J Interferon Cytokine Res 2001; 21: 861-9
151. Emilie D, Burgard M, Lascoux-Combe C, et al. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS 2001; 15: 1435-7
152. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91: 4082-5
153. Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr Opin Oncol 2000; 12: 564-73
154. Fife K, Howard MR, Gracie F, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998; 9: 751-5
155. Politi P, Reboredo G, Losso M, et al. Phase I trial of thalidomide in AIDS-related KS [abstract]. Proc Am Soc Clin Oncol 1998; 17: 45
156. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18: 2593-602
157. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835-46
158. Millauer B, Shawver LK, Plate KH, et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367: 576-9
159. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106
160. Miles SA, Arasteh K, Gill P, et al. A multicenter dose-escalating study of SU5416 in AIDS-related Kaposi's sarcoma [abstract]. Proc Am Soc Clin Oncol 2000; 19: 176a
161. Via LE, Gore-Langton RE, Pluda JM. Clinical trials referral resource: current clinical trials administering the antiangiogenesis agent SU5416. Oncology 2000; 14: 1312-23
162. Mesters RM, Padro T, Bieker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 2001; 98: 241-3
163. Tulpule A, Scadden DT, Espina BM, et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18: 716-23
164. Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998; 16: 1444-9
165. Sternlicht MD, Bergers G. Matrix metalloproteinases are emerging targets in anticancer therapy; status and prospects. Emerging Ther Targets 2000; 4: 609-33
166. Rader C, Popkov M, Neves JA, et al. Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. FASEB J 2002; 16: 2000-2